New data presented today by researchers at Fox Chase Cancer Center indicates that circulating tumor DNA, or ctDNA, can effectively predict the risk of metastatic disease in patients undergoing bladder-sparing treatment for muscle-invasive bladder cancer, but is not a reliable indicator of local recurrence within the bladder itself.
The findings, unveiled today, suggest a potential refinement in treatment strategies for this aggressive cancer. Currently, patients diagnosed with muscle-invasive bladder cancer often face a difficult choice: radical cystectomy, the complete removal of the bladder, or bladder-sparing treatment, typically involving chemotherapy and radiation. The decision is often guided by an assessment of the cancer’s risk of spreading.
According to the research, ctDNA analysis – which detects fragments of tumor DNA circulating in the bloodstream – offers a promising tool for identifying patients who are at higher risk of the cancer metastasizing, and who might therefore benefit most from more aggressive surgical intervention. However, the study also clarifies that ctDNA levels do not accurately reflect the likelihood of the cancer recurring within the bladder after bladder-sparing treatment.
The ability to more accurately predict metastatic risk could lead to a reduction in unnecessary bladder removals, improving quality of life for patients who can be safely treated with less invasive methods. Fox Chase Cancer Center has been at the forefront of research into bladder cancer diagnostics and treatment, and these latest findings build upon previous work exploring the potential of liquid biopsies – tests performed on blood samples – to guide clinical decision-making.
Researchers at Fox Chase Cancer Center have also recently secured funding to investigate methods for reducing treatment toxicity in bladder cancer patients, signaling a continued commitment to improving both the effectiveness and tolerability of cancer therapies. This separate line of inquiry aims to address the significant side effects often associated with chemotherapy and radiation, potentially allowing for more patients to benefit from bladder-sparing approaches.
The implications of this research are still being evaluated, and further studies are planned to validate these findings in larger patient cohorts. Fox Chase Cancer Center has not yet announced any immediate changes to its clinical protocols based on this data, but researchers indicated that they are actively working to integrate ctDNA analysis into their risk assessment models.
